Drugs in development · updated 11 November 2026
ST-1898: clinical trials and development status
As of 11 November 2026 ST-1898 is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 2 diseases. The most advanced phase is II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
An orally bioavailable small molecule inhibitor of multiple receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, multi-kinase inhibitor ST-1898 inhibits the activity of multiple RTKs, which may include vascular endothelial growth factor receptor 2 (VEGFR-2; VEGFR2), hepatocyte growth factor receptor (HGFR; c-Met), AXL (UFO), platelet-derived growth factor receptor alpha (PDGFRa), rearranged during transfection (RET) and mast/stem cell factor receptor c-Kit (SCFR; CD117). This may result in antitumor activity in tumor cells in which these RTKs are upregulated or dysregulated.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Melanoma | I–II | 1 | NCT06359860 |
| Renal cell carcinoma | I–II | 1 | NCT06127238 |
Everything on ST-1898
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.